We are live on ! Find out more
INO icon

Inovio Pharmaceuticals

54 hedge funds and large institutions have $50.6M invested in Inovio Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

222% more capital invested

Capital invested by funds: $15.7M → $50.6M (+$34.8M)

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

54% more funds holding

Funds holding: 3554 (+19)

0.09% more ownership

Funds ownership: 0.08%0.17% (+0.09%)

Holders
54
Holders Change
+19
Holders Change %
+54.29%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
16
Reduced
6
Closed
5
Calls
Puts
Net Calls
Net Calls Change

INO Hedge Fund Activity: Q4 2013 in Review

54 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2013, worth a combined $50.6M — up 222% from $15.7M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new INO positions and 5 closed out — a net gain of 20 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was State Street, adding an estimated $15.4M. The largest seller was Moore Capital Management, exiting entirely with an estimated $207K sold.

  • 54 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2013, up from 35 in Q3 2013.
  • Funds reported $50.6M of Inovio Pharmaceuticals stock for Q4 2013, up 222% quarter-over-quarter.
  • 25 funds opened new Inovio Pharmaceuticals positions in Q4 2013 and 5 closed out, a net change of +20 holders.
  • The largest Inovio Pharmaceuticals buyer in Q4 2013 was State Street, an estimated $15.4M added.
  • The largest Inovio Pharmaceuticals seller in Q4 2013 was Moore Capital Management, an estimated $207K sold.

Based on aggregated 13F filings for Q4 2013.